Invivyd Q1 2024 Earnings Report
Key Takeaways
Invivyd launched PEMGARDA in the U.S. for COVID-19 pre-exposure prophylaxis and reported interim data from the CANOPY Phase 3 trial. The company ended Q1 with $189.4 million in cash and expects to end 2024 with at least $75 million based on anticipated revenue of $150-$200 million.
Launched PEMGARDA in the U.S. for COVID-19 pre-exposure prophylaxis.
Reported interim exploratory COVID-19 clinical event data from CANOPY Phase 3 clinical trial of VYD222.
Received product-specific reimbursement codes covering PEMGARDA from CMS, covering approximately half of the target population.
Announced plans to pursue rapid immunobridging pathway to potential EUA for COVID-19 treatment.
Invivyd
Invivyd
Forward Guidance
Invivyd expects to end 2024 with at least $75 million in cash and cash equivalents, based on anticipated 2024 net product revenue of $150-$200 million and recent resource realignment.